Diabetes Health Professional
Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Professional Issues Archives
Print | Email | Share | Comments (6)

Survey Says Most Endocrinologists and Physicians See a Need for More Byetta and Januvia-Type Drugs

Jul 25, 2009

High percentages of endocrinologists, primary care physicians, and managed care organizations surveyed by a research firm say they would like to see additional GLP-1 analogues like Amylin/Eli Lilly's Byetta® and DPP-IV inhibitors like Merck's Januvia® available to treat type 2 diabetes.

The survey, "A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors?," published by Waltham, Mass.-based Decision Resources, queried 77 primary care physicians, 72 endocrinologists, and 20 pharmacy directors of managed care organizations:

Regarding new GLP-1 analogues, 89 percent of the endocrinologists, 77 percent of the primary care physicians, and 75 percent of MCO pharmacy directors said they would like to have additional therapies available in that category.

Regarding DPP-IV therapies, 71 percent of the endocrinologists, 74 percent of the primary care physicians, and 70 percent of MCO pharmacy directors said they would like to see additional therapies offered in that category.

In explaining their answers, survey respondents indicated their concerns with Byetta and Januvia. They cited the need for frequent injections with Byetta (twice daily*) and its record of causing severe nausea in some patients. With Januvia, their concerns were with the drug's inability to lower glucose levels as well as the conventional diabetes drug metformin, and questions about its long-term safety.

The criteria respondents cited for adding new GLP-1 therapies included a less frequent need for injections and a lessening of nausea-producing effects. With DPP-IV therapies, they said that an increased ability to lower BG levels would favorably influence their decision to stock or prescribe new drugs in that category.

* A long-range version of Byetta, injected once weekly, is now under review by the FDA. The French pharmaceutical company Sanofi-aventis is currently conducting trials on its own version of exenatide, the generic form of Byetta.


Categories: Byetta, Complications & Care, Diabetes, Diabetes, Endocrinology, Health Care, Professional Issues, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 6 comments - Jul 25, 2009

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.